Defence Therapeutics Inc (TSE:DTC) has released an update.
Defence Therapeutics Inc. has announced the promising results of a pre-clinical trial for its ARM-002 vaccine, targeting the challenging pancreatic cancer market. The vaccine, notably effective when used alongside an anti-PD-1 immune-checkpoint inhibitor, showcased significant tumor growth inhibition in test animals, marking a potential breakthrough in ‘hard-to-treat’ cancers. The company aims to adapt this proprietary technology to benefit cancer patients, with pancreatic cancer treatment market projections estimated to reach USD 36 billion by 2036.
For further insights into TSE:DTC stock, check out TipRanks’ Stock Analysis page.
